nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.05.2015 | Movement Disorders (M Okun, Section Editor)

The Prion Hypothesis of Parkinson’s Disease

verfasst von: Yaping Chu, Jeffrey H. Kordower

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

The discovery of alpha-synuclein’s prion-like behaviors in mammals, as well as a non-Mendelian type of inheritance, has led to a new concept in biology, the “prion hypothesis” of Parkinson’s disease. The misfolding and aggregation of alpha-synuclein (α-syn) within the nervous system occur in many neurodegenerative diseases including Parkinson’s disease (PD), Lewy body dementia (LBD), and multiple system atrophy (MSA). The molecular basis of synucleinopathies appears to be tightly coupled to α-syn’s conformational conversion and fibril formation. The pathological form of α-syn consists of oligomers and fibrils with rich in β-sheets. The conversion of its α-helical structure to the β-sheet rich fibril is a defining pathologic feature of α-syn. These kinds of disorders have been classified as protein misfolding diseases or proteopathies which share key biophysical and biochemical characteristics with prion diseases. In this review, we highlight α-syn’s prion-like activities in PD and PD models, describe the idea of a prion-like mechanism contributing to PD pathology, and discuss several key molecules that can modulate the α-syn accumulation and propagation.

Boassa D, Berlanga ML, Yang MA, et al. Mapping the subcellular distribution of α-synuclein in neurons using genetically encoded probes for correlated light and electron microscopy: implications for Parkinson’s disease pathogenesis. J Neurosci. 2013;6:2605–15.

Kontopoulos E, Parvin JD, Feany MB. Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet. 2006;15:3012–23.PubMed

Raghavan R, Kruijff L, Sterrenburg MD, et al. Alpha-synuclein expression in the developing human brain. Pediatr Dev Pathol. 2004;7:506–16.PubMed

Solano SM, Miller DW, Augood SJ, et al. Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson’s disease. Ann Neurol. 2000;47:201–10.PubMed

Kahle P, Neumann M, Ozmen L, et al. Subcellular localization of wild-type and Parkinson’s disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J Neurosci. 2000;20:6365–73.PubMed

Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science. 2000;287:1265–9.PubMed

van der Putten H, Wiederhold KH, Probst A, et al. Neuropathology in mice expressing human alpha-synuclein. J Neurosci. 2000;20:6021–9.PubMed

Stefanova N, Klimaschewski L, Poewe W, et al. Glial cell death induced by overexpression of alpha-synuclein. J Neurosci Res. 2001;65:432–8.PubMed

Miller DW, Johnson JM, Solano SM, et al. Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J Neural Transm. 2005;112:1613–24.PubMed

10.

Reyes JF, Rey NL, Bousset L, et al. Alpha-synuclein transfers from neurons to oligodendrocytes. Glia. 2014;62:387–98.PubMed

11.

Tu PH, Galvin JE, Baba M, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol. 1998;44:415–22.PubMed

12.

Arai T, Uéda K, Ikeda K, et al. Argyrophilic glial inclusions in the midbrain of patients with Parkinson’s disease and diffuse Lewy body disease are immunopositive for NACP/alpha-synuclein. Neurosci Lett. 1999;259:83–6.PubMed

13.

Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H. NACP/alpha-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson’s disease brains. Acta Neuropathol. 2000;99:14–20.PubMed

14.

Kordower JH, Chu Y, Hauser RA, et al. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat Med. 2008;14(5):504–6.PubMed

15.

Li JY, Englund E, Holton JL. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med. 2008;14:501–3.PubMed

16.

Chu Y, Kordower JH. Lewy body pathology in fetal grafts. Ann N Y Acad Sci. 2010;1184:55–67.PubMed

17.

Kordower JH, Brundin P. Propagation of host disease to grafted neurons: accumulating evidence. Exp Neurol. 2009;220:224–5.PubMed

18.

Angot E, Brundin P. Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson’s disease. Parkinsonism Relat Disord. 2009;3:S143–7.

19.

Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci. 2010;11:155–9.PubMedCentralPubMed

20.

Goedert M. Human beta-synuclein rendered fibrillogenic by designed mutations. J Biol Chem. 2010;285:38555–67.PubMedCentralPubMed

21.

Angot E, Steiner JA, Hansen C, et al. Are synucleinopathies prion-like disorders? Lancet Neurol. 2010;9:1128–38.PubMed

22.••

Luk KC, Kehm V, Carroll J, et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338:949–53. This paper first revealed that intrastriatal inoculation of synthetic alpha-synuclein fibrils led to the cell-to-cell transmission of pathologic alpha-synuclein in non-transgenic mice. (1) Synthetic alpha-synuclein fibrils can promote fibrillization of monomeric alpha-synuclein that likes the feature of prion protein (PrP ^SC ). (2) Misfolded form of alpha-synuclein can spread from one neuron to another like prion protein (PrP ^SC ), acting as “seeds” that eventually affect most of the interconnected cells. (3) Lewy pathology accumulation resulted in progressive loss of dopamine neurons and motor deficits. This study explains the neurodegenerative mechanism of Parkinson’s disease.

23.•

Recasens A, Dehay B, Bové J, et al. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol. 2014;75(3):351–62. This paper demonstrated that intranigral or intrastriatal inoculations of PD-derived LB extracts resulted in progressive nigrostriatal neurodegeneration starting at striatal dopaminergic terminals. This study further indicated that the Lewy body is pathogen and dopaminergic neurodegeneration starts from terminals.PubMed

24.

Wu KP, Weinstock DS, Narayanan C, et al. Structural reorganization of alpha-synuclein at low pH observed by NMR and REMD simulations. J Mol Biol. 2009;391:784–96.PubMedCentralPubMed

25.

Vekrellis K, Rideout HJ, Stefanis L. Neurobiology of alpha-synuclein. Mol Neurobiol. 2004;30:1–21.PubMed

26.

Chu Y, Kordower JH. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson’s disease? Neurobiol Dis. 2007;25(1):134–49.PubMed

27.

Pan KM, Baldwin M, Nguyen J, et al. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc Natl Acad Sci U S A. 1993;90:10962–6.PubMedCentralPubMed

28.

Wood SJ, Wypych J, Steavenson S, et al. Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson’s disease. J Biol Chem. 1999;274(28):19509–12.PubMed

29.

Yonetani M, Nonaka T, Masuda M, et al. Conversion of wild-type alpha-synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. J Biol Chem. 2009;284:7940–50.PubMedCentralPubMed

30.

Uversky VN, Li J, Fink AL. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem. 2001;276:10737–44.PubMed

31.

Takahashi T, Yamashita H, Nakamura T, et al. Tyrosine 125 of alpha-synuclein plays a critical role for dimerization following nitrative stress. Brain Res. 2002;938:73–80.PubMed

32.

Zhou W, Freed CR. Tyrosine-to-cysteine modification of human alpha-synuclein enhances protein aggregation and cellular toxicity. J Biol Chem. 2004;279:10128–35.PubMed

33.

Krishnan S, Chi EY, Wood SJ, et al. Oxidative dimer formation is the critical rate-limiting step for Parkinson’s disease alpha-synuclein fibrillogenesis. Biochemistry. 2003;42:829–37.PubMed

34.

Pivato M, De Franceschi G, Tosatto L, et al. Covalent α-synuclein dimers: chemico-physical and aggregation properties. PLoS One. 2012;7:e50027.PubMedCentralPubMed

35.

Serpell LC, Berriman J, Jakes R, et al. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A. 2000;97:4897–902.PubMedCentralPubMed

36.

Crowther RA, Daniel SE, Goedert M. Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson’s disease brain. Neurosci Lett. 2000;292:128–30.PubMed

37.

Sacino AN, Thomas MA, Ceballos-Diaz C, et al. Conformational templating of α-synuclein aggregates in neuronal-glial cultures. Mol Neurodegener. 2013;8:1–17.

38.

Luk KC, Song C, O’Brien P. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. Proc Natl Acad Sci U S A. 2009;106:20051–6.PubMedCentralPubMed

39.•

Sacino AN, Brooks M, McKinney AB, et al. Brain injection of α-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker. J Neurosci. 2014;34:12368–78. This paper demonstrates that intracerebral injection of recombinant amyloidogenic or soluble alpha-synuclein induces extensive alpha-synuclein intracellular inclusion pathology. The pathology includes a broader disruption of proteostasis and glial activation. This study suggests that exogenous amyloidogenic or soluble alpha-synuclein seeding intrigued multiple interdependent mechanisms of synucleinopathy.PubMed

40.

Lee HJ, Suk JE, Bae EJ, et al. Assembly-dependent endocytosis and clearance of extracellular alpha-synuclein. Int J Biochem Cell Biol. 2008;40:1835–49.PubMed

41.

Freundt EC, Maynard N, Clancy EK, et al. Neuron-to-neuron transmission of α-synuclein fibrils through axonal transport. Ann Neurol. 2012;72:517–24.PubMedCentralPubMed

42.

Lee HJ, Patel S, Lee SJ. Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. Neuroscience. 2005;25:6016–24.PubMed

43.

Nishioka K, Hayashi S, Farrer MJ, et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson’s disease. Ann Neurol. 2006;59:298–309.PubMed

44.

Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus triplication causes Parkinson’s disease. Science. 2003;302:841.PubMed

45.

Kirik D, Björklund A. Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors. Trends Neurosci. 2003;26:386–92.PubMed

46.

Chu Y, Goldman JG, Kelly L, et al. Abnormal alpha-synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental Parkinson’s disease. Neurobiol Dis. 2014;69:1–14.PubMed

47.

Gründemann J, Schlaudraff F, Haeckel O, Liss B. Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson’s disease. Nucleic Acids Res. 2008;36(7):e38.PubMedCentralPubMed

48.

Winkler S, Hagenah J, Lincoln S, et al. Alpha-synuclein and Parkinson disease susceptibility. Neurology. 2007;69:1745–50.PubMed

49.

Fuchs J, Tichopad A, Golub Y, et al. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J. 2008;22:1327–34.PubMed

50.

Mata IF, Shi M, Agarwal P, et al. SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol. 2010;67:1350–6.PubMedCentralPubMed

51.

Satake W, Nakabayashi Y, Mizuta I, et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson’s disease. Nat Genet. 2009;41:1303–7.PubMed

52.

Simon-Sanches J. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. 2009.

53.

Simón-Sánchez J, Schulte C, Bras JM, et al. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet. 2009;41:1308–12.PubMedCentralPubMed

54.

Matsumoto L, Takuma H, Tamaoka A, et al. CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson’s disease. PLoS One. 2010;5(11):e15522.PubMedCentralPubMed

55.

Desplats P, Spencer B, Coffee E, et al. Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases. J Biol Chem. 2011;286:9031–7.PubMedCentralPubMed

56.

Angeles DC, Gan BH, Onstead L, et al. Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death. Hum Mutat. 2011;32:1390–7.PubMed

57.

Angeles DC, Ho P, Chua LL, et al. Thiol peroxidases ameliorate LRRK2 mutant-induced mitochondrial and dopaminergic neuronal degeneration in Drosophila. Hum Mol Genet. 2014;23:3157–65.PubMed

58.

Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci. 2003;4:49–60.PubMed

59.

Winklhofer KF, Tatzelt J, Haass C. Observing fibrillar assemblies on scrapie-infected cells. EMBO J. 2008;27(2):336–49.PubMedCentralPubMed

60.

Volles MJ, Lansbury Jr PT. Relationships between the sequence of alpha-synuclein and its membrane affinity, fibrillization propensity, and yeast toxicity. J Mol Biol. 2007;366:1510–22.PubMedCentralPubMed

61.

Gorbatyuk OS, Li S, Sullivan LF, et al. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci U S A. 2008;105:763–8.PubMedCentralPubMed

62.

Anderson JP, Walker DE, Goldstein JM, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Clin Epidemiol. 2007;60:300–8.PubMed

63.

Wang Y, Shi M, Chung KA, et al. Phosphorylated α-synuclein in Parkinson’s disease. Sci Transl Med. 2012;4(121):121ra20.PubMedCentralPubMed

64.

Shults CW, Rockenstein E, Crews L, et al. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J Neurosci. 2005;25:10689–99.PubMed

65.

Sato H, Kato T, Arawaka S. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson’s disease: a review of in vivo models. Rev Neurosci. 2013;24:115–23.PubMed

66.

Lee KW, Chen W, Junn E, et al. Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model. J Neurosci. 2011;31:6963–71.PubMed

67.

Chu Y, Le W, Kompoliti K, et al. Nurr1 in Parkinson’s disease and related disorders. J Comp Neurol. 2006;494:495–514.PubMedCentralPubMed

68.

Chu Y, Mickiewicz AL, Kordower JH. α-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson’s disease. Neurobiol Dis. 2011;41:71–82.PubMed

69.

Chu Y, Dodiya H, Aebischer P, et al. Alterations in lysosomal and proteasomal markers in Parkinson’s disease: relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009;35:385–98.PubMed

70.

Chu Y, Morfini GA, Langhamer LB, et al. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson’s disease. Brain. 2012;135:2058–73.PubMed

71.

Lindersson EK, Højrup P, Gai WP, et al. Alpha-Synuclein filaments bind the transcriptional regulator HMGB-1. Neuroreport. 2004;15:2735–9.PubMed

72.

Bianchi ME, Agresti A. HMG proteins: dynamic players in gene regulation and differentiation. Curr Opin Genet Dev. 2005;15:496–506.PubMed

73.

Klune JR, Dhupar R, Cardinal J, et al. HMGB1: endogenous danger signaling. Mol Med. 2008;14(7–8):476–84.PubMedCentralPubMed

74.

Jeffrey M, Martin S, González L, et al. Immunohistochemical features of PrP(d) accumulation in natural and experimental goat transmissible spongiform encephalopathies. J Comp Pathol. 2006;134:171–81.PubMed

75.

Press CM, Heggebø R, Espenes A. Involvement of gut-associated lymphoid tissue of ruminants in the spread of transmissible spongiform encephalopathies. Adv Drug Deliv Rev. 2004;56(6):885–99.PubMed

76.

Race R, Oldstone M, Chesebro B. Entry versus blockade of brain infection following oral or intraperitoneal scrapie administration: role of prion protein expression in peripheral nerves and spleen. J Virol. 2000;74:828–33.PubMedCentralPubMed

77.

McBride PA, Schulz-Schaeffer WJ, Donaldson M, et al. Early spread of scrapie from the gastrointestinal tract to the central nervous system involves autonomic fibers of the splanchnic and vagus nerves. J Virol. 2001;75:9320–7.PubMedCentralPubMed

78.

Mabbott NA, MacPherson GG. Prions and their lethal journey to the brain. Nat Rev Microbiol. 2006;4:201–11.PubMed

79.

Rodolfo K, Hässig R, Moya KL, et al. A novel cellular prion protein isoform present in rapid anterograde axonal transport. Neuroreport. 1999;10:3639–44.PubMed

80.

Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24:197–211.PubMed

81.

Braak H, Del Tredici K. Neuroanatomy and pathology of sporadic Parkinson’s disease. Adv Anat Embryol Cell Biol. 2009;201:1–119.PubMed

82.

Del Tredici K, Braak H. A not entirely benign procedure: progression of Parkinson’s disease. Acta Neuropathol. 2008;115:379–84.PubMed

83.

Shannon KM, Keshavarzian A, Dodiya HB, et al. Is alpha-synuclein in the colon a biomarker for premotor Parkinson’s disease? Evidence from 3 cases. Mov Disord. 2012;27:716–9.PubMed

84.

Bloch A, Probst A, Bissig H, et al. Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol. 2006;32:284–95.PubMed

85.

Braak H, Sastre M, Bohl JR, et al. Parkinson’s disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol. 2007;113:421–9.PubMed

86.

Minguez-Castellanos A, Chamorro CE, Escamilla-Sevilla F, et al. Do alpha-synuclein aggregates in autonomic plexuses predate Lewy body disorders?: a cohort study. Neurology. 2007;68:2012–8.PubMed

87.

Cersosimo MG, Benarroch EE. Autonomic involvement in Parkinson’s disease: pathology, pathophysiology, clinical features and possible peripheral biomarkers. J Neurol Sci. 2012;313:57–63.PubMed

88.

Ulusoy A, Rusconi R, Pérez-Revuelta BI, et al. Caudo-rostral brain spreading of α-synuclein through vagal connections. EMBO Mol Med. 2013;5:1051–9.PubMedCentralPubMed

89.

Beach TG, Adler CH, Sue LI. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010;119:689–702.PubMedCentralPubMed

90.

Ansari KA, Johnson A. Olfactory function in patients with Parkinson’s disease. J Chronic Dis. 1975;28:493–7.PubMed

91.

Constantinidis J, de Ajuriaguerra J. Familial syndrome with parkinsonian tremor and anosmia and its therapy with L-dopa associated with a decarboxylase inhibitor. Therapeutique. 1970;46:263–9.PubMed

92.

Kissel P, Andre JM. Parkinson’s disease and anosmia in monozygotic twin sisters. J Genet Hum. 1976;24(2):113–7.PubMed

93.

Doty RL, Deems DA, Frye RE, et al. Olfactory sensitivity, nasal resistance, and autonomic function in patients with multiple chemical sensitivities. Arch Otolaryngol Head Neck Surg. 1988;114:1422–7.PubMed

94.

Braak H, Müller CM, Rüb U, et al. Pathology associated with sporadic Parkinson’s disease–where does it end? J Neural Transm Suppl. 2006;70:89–97.PubMed

95.

Del Tredici K, Braak H. Lewy pathology and neurodegeneration in premotor Parkinson’s disease. Mov Disord. 2012;27:597–607.PubMed

96.

Tolosa E, Pont-Sunyer C. Progress in defining the premotor phase of Parkinson’s disease. J Neurol Sci. 2011;310:4–8.PubMed

97.

Kordower HJ, Chu Y, Muller S, et al. Intrastriatal alpha synuclein preformed fibrils in macaque monkeys: neuronal transport, long-term imaging and neuropathologic changes. Soc Neurosci 2014; abstract 409. 07/I11.

98.

Rosenbluth J, Wissig SL. The distribution of exogenous ferritin in toda spinal ganglia and the mechanism of its uptake by neurons. J Cell Biol. 1964;23:307–25.PubMedCentralPubMed

99.

Schmid SL, Fuchs R, Male P, Mellman I. Two distinct subpopulations of endosomes involved in membrane recycling and transport to lysosomes. Cell. 1988;52:73–83.PubMed

100.

Neutra MR, Ciechanover A, Owen LS, Lodish HF. Intracellular transport of transferrin- and asialoorosomucoid-colloidal gold conjugates to lysosomes after receptor-mediated endocytosis. Histochem Cytochem. 1985;33:1134–44.

101.

Auluck PK, Caraveo G, Lindquist S. α-Synuclein: membrane interactions and toxicity in Parkinson’s disease. Annu Rev Cell Dev Biol. 2010;26:211–33.PubMed

102.

Kawamata H, McLean PJ, Sharma N, Hyman BT. Interaction of alpha-synuclein and synphilin-1: effect of Parkinson’s disease-associated mutations. J Neurochem. 2001;77:929–34.PubMed

103.

Ribeiro CS, Carneiro K, Ross CA, et al. Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by alpha-synuclein. J Biol Chem. 2002;277:23927–33.PubMed

104.

Wakabayashi K, Engelender S, Tanaka Y, et al. Immunocytochemical localization of synphilin-1, an alpha-synuclein-associated protein, in neurodegenerative disorders. Acta Neuropathol. 2002;103:209–14.PubMed

105.

Engelender S, Kaminsky Z, Guo X, et al. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genet. 1999;22:110–4.PubMed

106.

Neystat M, Rzhetskaya M, Kholodilov N, Burke RE. Analysis of synphilin-1 and synuclein interactions by yeast two-hybrid beta-galactosidase liquid assay. Neurosci Lett. 2002;325:119–23.PubMed

107.

Alvarez-Erviti L, Seow Y, Schapira AH, et al. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol Dis. 2011;42(3):360–7.PubMedCentralPubMed

108.

Lee HJ, Suk JE, Patrick C, et al. Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies. J Biol Chem. 2010;285:9262–72.PubMedCentralPubMed

109.

Block ML, Hong JS. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans. 2007;35:1127–32.PubMed

110.

Gao HM, Hong JS. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol. 2008;29(8):357–65.PubMed

111.

Hirsch EC, Hunot S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol. 2009;8:382–97.PubMed

112.

Tansey MG, McCoy MK, Frank-Cannon TC. Neuroinflammatory mechanisms in Parkinson’s disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol. 2007;208:1–25.PubMedCentralPubMed

113.

Béraud D, Twomey M, Bloom B, et al. α-Synuclein alters toll-like receptor expression. Front Neurosci. 2011;5:80.PubMedCentralPubMed

114.

Roodveldt C, Christodoulou J, Dobson CM. Immunological features of alpha-synuclein in Parkinson’s disease. J Cell Mol Med. 2008;12:1820–9.PubMed

115.

Zhang W, Wang T, Pei Z, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB J. 2005;19:533–42.PubMed

116.

Reynolds AD, Glanzer JG, Kadiu I, et al. Nitrated alpha-synuclein-activated microglial profiling for Parkinson’s disease. J Neurochem. 2008;104:1504–25.PubMed

117.

Theodore S, Cao S, McLean PJ, Standaert DG. Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J Neuropathol Exp Neurol. 2008;67(12):1149–58.PubMedCentralPubMed

118.

Federico A, Cardaioli E, Da Pozzo P, et al. Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci. 2012;322:254–62.PubMed

119.

Su X, Federoff HJ, Maguire-Zeiss KA. Mutant alpha-synuclein overexpression mediates early proinflammatory activity. Neurotox Res. 2009;16:238–54.PubMedCentralPubMed

120.

Alvarez-Erviti L, Couch Y, Richardson J, et al. Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. Neurosci Res. 2011;69:337–42.PubMed

121.

Ferrari CC, Pott Godoy MC, Tarelli R, et al. Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. Neurobiol Dis. 2006;24:183–93.PubMed

122.

Couch Y, Alvarez-Erviti L, Sibson NR, et al. The acute inflammatory response to intranigral α-synuclein differs significantly from intranigral lipopolysaccharide and is exacerbated by peripheral inflammation. J Neuroinflammation. 2011;8:166.PubMedCentralPubMed

123.

Danielson SR, Held JM, Schilling B, et al. Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson’s disease. Anal Chem. 2009;81:7823–8.PubMedCentralPubMed

124.

Gao HM, Kotzbauer PT, Uryu K, et al. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci. 2008;28:7687–98.PubMedCentralPubMed

125.

Benner EJ, Banerjee R, Reynolds AD, et al. Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS One. 2008;3:e1376.PubMedCentralPubMed

126.

Tanaka S, Ishii A, Ohtaki H, et al. Activation of microglia induces symptoms of Parkinson’s disease in wild-type, but not in IL-1 knockout mice. J Neuroinflammation. 2013;10:143.PubMedCentralPubMed

127.

Kelly LP, Carvey PM, Keshavarzian A, et al. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson’s disease. Mov Disord. 2014;29:999–1009.PubMed

128.

Gao HM, Jiang J, Wilson B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson’s disease. J Neurochem. 2002;81:1285–97.PubMed

129.

Ling Z, Zhu Y, Tong C, et al. Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally. Exp Neurol. 2006;199:499–512.PubMed

130.

Qin J, Goswami R, Balabanov R, Dawson G. Oxidized phosphatidylcholine is a marker for neuroinflammation in multiple sclerosis brain. J Neurosci Res. 2007;85:977–84.PubMed

131.

Zhou Y, Zhang Y, Li J, et al. A comprehensive study on long-term injury to nigral dopaminergic neurons following intracerebroventricular injection of lipopolysaccharide in rats. J Neurochem. 2012;123:771–80.PubMed

132.

He Q, Yu W, Wu J, et al. Intranasal LPS-mediated Parkinson’s model challenges the pathogenesis of nasal cavity and environmental toxins. PLoS One. 2013;8:e78418.PubMedCentralPubMed

133.

Tokuda T, Qureshi MM, Ardah MT, et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology. 2010;75:1766–72.PubMed

134.

Park MJ, Cheon SM, Bae HR, et al. Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson’s disease. J Clin Neurol. 2011;7(4):215–22.PubMedCentralPubMed

135.

Compta Y, Valente T, Saura J, et al. Correlates of cerebrospinal fluid levels of oligomeric- and total-α-synuclein in premotor, motor and dementia stages of Parkinson’s disease. J Neurol. 2014 Nov 8. [Epub ahead of print].

136.

Brown DR. Oligomeric alpha-synuclein and its role in neuronal death. IUBMB Life. 2010;62:334–9.PubMed

137.

Vekrellis K, Xilouri M, Emmanouilidou E, et al. Pathological roles of α-synuclein in neurological disorders. Lancet Neurol. 2011;10:1015–25.PubMed

138.

Winner B, Jappelli R, Maji SK, et al. In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A. 2011;108:4194–9.PubMedCentralPubMed

139.

Emmanouilidou E, Melachroinou K, Roumeliotis T, Garbis SD, et al. Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. J Neurosci. 2010;30:6838–51.PubMedCentralPubMed

140.

Su X, Maguire-Zeiss KA, Giuliano R, et al. Synuclein activates microglia in a model of Parkinson’s disease. Neurobiol Aging. 2008;29:1690–701.PubMedCentralPubMed

141.

Bartels AL, Willemsen AT, Kortekaas R, et al. Decreased blood–brain barrier P-glycoprotein function in the progression of Parkinson’s disease, PSP and MSA. J Neural Transm. 2008;115:1001–9.PubMedCentralPubMed

142.

Kortekaas R, Leenders KL, van Oostrom JC, et al. Blood–brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol. 2005;57:176–9.PubMed

143.

Sierks MR, Chatterjee G, McGraw C, et al. CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integr Biol (Camb). 2011;3:1188–96.

Titel: The Prion Hypothesis of Parkinson’s Disease
verfasst von: Yaping Chu
Jeffrey H. Kordower
Publikationsdatum: 01.05.2015
Verlag: Springer US
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 5/2015
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-015-0549-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The Prion Hypothesis of Parkinson’s Disease

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2015

Infantile-Onset Saccade Initiation Delay (Congenital Ocular Motor Apraxia)

Sleep Disorders in Multiple Sclerosis. Review

Clinical Utility of Ocular Vestibular-Evoked Myogenic Potentials (oVEMPs)

Glutamate and GABA Imbalance Following Traumatic Brain Injury

Development of Regional Stroke Programs

Migraine Management in Children

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Frühe Alzheimertherapie lohnt sich

Viel Bewegung in der Parkinsonforschung

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Neurologie